Published Date: 20-11-2018
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report LAMEA Stroke Management Market, published by KBV research, the LAMEA Stroke Management Market would witness market growth of 8.0% CAGR during the forecast period (2018 – 2024).
The Brazil market would dominate the LAMEA Ischemic Stroke Management Market by Country 2017, and would continue to be a dominant market till 2024; thereby, achieving a market value of $898.3 million by 2024, growing at a CAGR of 7.2 % during the forecast period. The Argentina market is expected to witness a CAGR of 7.2% during (2018 - 2024). Additionally, The UAE market is expected to witness a CAGR of 4.3% during (2018 - 2024).
The Diagnostics market dominated the UAE Stroke Management Market by Type 2017, and would achieve a market value of $516.7 million by 2024, growing at a CAGR of 5.3 % during the forecast period. The Therapeutics market is expected to witness highest CAGR of 6.9% during (2018 - 2024).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of ABBOTT Laboratories, B. Braun Melsungen Ag, Boston Scientific Corporation, Cardinal Health, Inc., Ge Healthcare, Glaxosmithkline Plc, Medtronic Plc., Siemens Aktiengesellschaft, Merck & Co., Inc., and Bristol-Myers Squibb Company.
Unique Offerings from KBV Research